MAIA (MAIA Biotechnology) יחס שווי שוק לשווי בספרים

MAIA Biotechnology (MAIA) is developing targeted tumor combat methods, leveraging intellectual property in telomere modulation to secure future royalties. The business is built upon the THIO ecosystem, where inhibitor patents link the company to oncology centers through clinical protocols. The current metric stands at 3.25. The market price, as confirmed by this chart, complements data regarding intensive R&D and the preparation of breakthrough lung cancer drugs.

MAIA Biotechnology is developing a unique oncology therapy based on the forced senescence of cancer cells by targeting telomeres. This multiple compares the current market value of the shares with the issuer's net assets. By analyzing the market-to-book ratio on GURU.Markets, one can assess the size of the premium for intellectual capital. This chart reflects market expectations regarding the success of genetic developments. High values confirm investors' willingness to pay a premium for the potential of an innovative breakthrough.